|Systematic (IUPAC) name|
|(S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide|
|Mol. mass||296.320 g/mol|
Eslicarbazepine acetate (brand names Aptiom, Zebinix, Exalief), abbreviated as ESL, is an anticonvulsant approved for use in Europe and the United States as an adjunctive therapy for epilepsy.
Similarly to oxcarbazepine, ESL behaves as a prodrug to eslicarbazepine ((S)-(+)-licarbazepine). As such, their mechanisms of action are identical. However, there may be pharmacokinetic differences between the two drugs; for instance, ESL may not produce as high of peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine, which could, in theory, improve tolerability.
- Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
- Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nat. Rev. Neurosci. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697.
|This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.|